Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 2/9/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Fred Eshelman?

Fred N. Eshelman

Board of Visitors

School of Pharmacy at UNC-CH

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

School of Pharmacy at UNC-CH

Find other employees at this company (1)

Background Information

Employment History

Chancellor

University of California , San Diego


Chancellor

North Carolina State University


Chancellor

University Professor Of Chemistry


Affiliations

Eshelman Ventures LLC

Founder


GlaxoSmithKline plc

Senior Vice President, Development and Member of the Board of Directors


The Medical Foundation of North Carolina Inc

Executive Committee


G1 Therapeutics , Inc.

Board Member


Valeant Pharmaceuticals International

Board Member


Innocrin Pharmaceuticals Inc

Board Member


Targanta Therapeutics Corp.

Board Member


Auven Therapeutics

Advisory Board Member


Neoantigenics Inc

Board Member


Medikidz Limited

Board Member


Cellective BioTherapy Inc

Board Member


AeroMD

Board Member


UNC School of Pharmacy

Board of Governors


InvestCorrectly

Board Member


The Medicines Company

Board Member


Eyenovia , Inc.

Board Member


Meryx , Inc.

Board Member


Dignify Therapeutic , Inc.

Board Member


Debt

Steering Committee Member


Carolina Business Coalition

Board Member


Princeton BioPharma Capital Partners LLC

Business Advisory Board Member


Association of Clinical Research Organizations

Board Member


Celtic Therapeutics

Advisory Board Member


Wilmington Chamber of Commerce

Board Member


Visitors

Member of the Pharmacy School's Board


Cellona Therapeutics

Advisory Board Member


Accelerator Corporation

Board Member


University of Cincinnati

Faculty Member


N.C. Medical Foundation

Executive Committee


Computer Solutions

Board Member


Aton Pharma , Inc.

Board Member


School of Ph..

Member


Princeton Pharma Holdings LLC.

Member, Board


Catalytix Inc

Board of Advisors Member


Oriel Therapeutics Inc.

Board Member


Spotlight Health Inc

Board Member


PRIMECYTE , Inc.

Board Member


PPGx

Board Member


Board of Visitors

Member


Gov. Beverly Perdue

Board of Trustees


Can.Board Listed/Public CompaniesThe Medicines Company

Board Member


SARCO , Inc.

Chair, Board of Directors


Pharm

Founder


PPD Inc

Chief Executive Officer


University of North Carolina

Board of Trustees


Education

B.S.

Harvard Business School


B.S.

pharmacy

University of North Carolina at Chapel Hill. He


BSc

pharmacy

UNC-CH


BSc

pharmacy

University of North Carolina , Chapel Hill


Graduate of the Owner/President Management program

Harvard Business School


Ph.D.

University of North Carolina-Chapel Hill


Pharm.D.

The School of Pharmacy at UNC Chapel Hill


bachelor's degree

High Point University


bachelor's degree

pharmacy

Carolina


doctorate

pharmacy

University of Cincinnati


Web References(183 Total References)


www.targanta.com

Fredric N. Eshelman, Pharm.D
Non-Executive Chairman, Member of Audit Committee Fredric N. Eshelman has been a director and chairman since August 2015. Dr. Eshelman has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. (PPD) and founding chairman of Furiex Pharmaceuticals, Inc. In 2014, Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014, Dr. Eshelman served as Chairman of the Board of Furiex. From 2009 to 2011, he served as Executive Chairman of PPD. He also served as Chief Executive Officer of PPD from 1990 to 2009 and as Vice Chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of AeroMD, Cellective Biotherapy, Inc., Dignify Therapeutic, Inc., Eyenovia, Inc., G1 Therapeutics, Inc., Innocrin Pharmaceuticals, Inc., Medikidz USA, Inc., Meryx, Inc. and Neoantigenics LLC and Valeant Pharmaceuticals International, Inc., and the advisory board of Auven Therapeutics. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina, was on the Board of Trustees for UNC-W and in 2011 was appointed by the NC General Assembly to serve on the Board of Governors for the state's multi-campus university system as well as the NC Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at UNC-CH. One of the top pharmacy programs in the United States, in May 2008 the school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession. Dr. Eshelman has received many awards including the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the NC Entrepreneur Hall of Fame Award. He has received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital and a BS in pharmacy from UNC-CH. He is a graduate of the OPM program at Harvard Business School.


www.eshelmanventures.com [cached]

Fred Eshelman is the founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies.
He often serves on the boards of portfolio companies. Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests. After PPD he served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals (FURX, NASDAQ), a company which licensed and rapidly developed new medicines. Furiex was sold to Forest Labs/Actavis in July, 2014. He is Chairman of The Medicines Company (MDCO, NASDAQ), and recently joined the board of Valeant Pharmaceuticals (VRX). His career has also included positions as senior vice president (development) and board member of the former Glaxo, Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Eshelman has served on the executive committee of the Medical Foundation of North Carolina, was on the Board of Trustees for UNC-W and in 2011 was appointed by the NC General Assembly to serve on the Board of Governors for the state's multi-campus university system as well as the NC Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at UNC-CH, which was recently named the number one pharmacy school in the US. In May 2008 the school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession. Eshelman has received many awards including the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the NC Entrepreneur Hall of Fame Award and the NC business hall of fame. He received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital and a BS in pharmacy from UNC-CH. He completed the OPM program at Harvard Business School.


cednc.org [cached]

Fred Eshelman to Receive Life Science Leadership Award at the CED Life Science Conference 2016
Life Sciences Press Releases Fred Eshelman to Receive Life Science Leadership Award at the CED Life Science Conference 2016 Fred Eshelman Eshelman Joins Speaker Lineup of Fourteen World-Renowned Industry Leaders DURHAM, NC - January 25, 2016 - The Council for Entrepreneurial Development (CED) today announced that Fred Eshelman will be presented with the Life Science Leadership Award at the 25th annual CED Life Science Conference (March 1-2, 2016 in Raleigh, NC). Eshelman will appear along with fourteen other confirmed speakers including global leaders in research, pharmaceuticals, biotechnology, medical device, and capital formation. Industry visionaries will converge with emerging entrepreneurs, investors, researchers, and professional service firms at the CED Life Science Conference, one of the leading life science gatherings in the nation that attracts over 1,000 participants each year. As founder, CEO and Executive Chairman of PPD as well as founding Chairman of Furiex Pharmaceuticals, Fred Eshelman has played a pivotal role in the development of the North Carolina life science community. Eshelman has served on the executive committee of the Medical Foundation of North Carolina, was on the Board of Trustees for the University of North Carolina at Wilmington, and was appointed by the NC General Assembly in 2011 to serve on the Board of Governors for the state's multi-campus university system as well as the North Carolina Biotechnology Center. He also chairs the board of visitors for the School of Pharmacy at the University of North Carolina at Chapel Hill. One of the top pharmacy programs in the United States, the school was named the UNC Eshelman School of Pharmacy in May 2008 in recognition of his many contributions to the school and the profession. Additionally, Eshelman has demonstrated an incredible commitment to growing and sustaining this community as a generous donor and investor with Eshelman Ventures. "I am honored to receive the 2016 Life Science Leadership Award at this celebrated annual gathering," said Eshelman. "I appreciate CED's work with many of the breakthrough companies in North Carolina and I am personally committed to the continued vibrancy of this region as a top life science cluster." "Fred Eshelman's leadership in our life science community offers great inspiration to emerging innovators, especially as he continues his commitment to invest back into the entrepreneurial ecosystem of North Carolina. Ernest Mario (Chairman of Chimerix., venture partner at Pappas Ventures), the 2015 recipient of the award, will introduce Eshelman at the conference and present him with the award. Fred Eshelman will also speak at the conference, along with some of the most celebrated industry leaders:


www.talent4boards.com

The Medicines Company appoints Fred Eshelman to its Board of Directors as Non-Executive Chairman
The Medicines Company appoints Fred Eshelman to its Board of Directors as Non-Executive Chairman - Talent4Boards Talent4Boards info@talent4boards.com HomeBoard - USA / Can.Board Listed/Public CompaniesThe Medicines Company appoints Fred Eshelman to its Board of Directors as Non-Executive Chairman The Medicines Company appoints Fred Eshelman to its Board of Directors as Non-Executive Chairman August 31, 2015 By Talent4Boards Team Comments are Off Board - USA / Can., Board Listed/Public Companies - USA, NJ - The Medicines Company (NASDAQ:MDCO) today announced that its Board of Directors has named Dr. Fred Eshelman, founder of Eshelman Ventures LLC, an investment company focused on healthcare companies, as non-executive Chairman of The Medicines Company Board of Directors, effective immediately. Dr. Eshelman has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. He is the founder and former Chief Executive Officer and Executive Chairman of Pharmaceutical Product Development, Inc. (PPD), a global contract pharmaceutical research organization providing drug discovery, development and lifecycle management services. Dr. Eshelman was also the founding chairman of Furiex Pharmaceuticals, Inc., a drug development company that collaborated with pharmaceutical and biotechnology companies to increase the value of their drug candidates by applying an accelerated approach to drug development. "Fred brings a breadth of skills and experiences in our industry and has a proven track record of building and leading businesses that create significant value for customers and for shareholders. I am delighted to welcome Fred as Chairman and believe he will be an instrumental partner in designing strategy and driving growth." "The Medicines Company has a range of very important assets that collectively represent diverse commercial opportunities, and I am honored to assume the role of Chairman at a point of unparalleled opportunity to grow the business and optimize the potential of the portfolio," said Dr. Eshelman. Prior to Dr. Eshelman joining the Board, Eshelman Ventures, LLC, an entity wholly owned by Dr. Eshelman, purchased from The Medicines Company $30 million of the Company's common stock. About Dr. Fred Eshelman In addition to Dr. Eshelman's roles at Eshelman Ventures, LLC, PPD and Furiex Pharmaceuticals, he has also served as Senior Vice President, Development and member of the Board of Directors of the former Glaxo, Inc., as well as in various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system as well as the North Carolina Biotechnology Center. He also chairs the board of visitors for the School of Pharmacy at UNC-Chapel Hill, which was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession. He has also served on the executive committee of the Medical Foundation of North Carolina and the Board of Trustees for UNC-Wilmington. Dr. Eshelman received his Doctor of Pharmacy from the University of Cincinnati, and completed a residency at Cincinnati General Hospital. He received a Bachelor of Science in pharmacy from UNC-Chapel Hill and is also a graduate of the Owner/President Management program at Harvard Business School.


www.accpri.org

Fred Eshelman
Fred Eshelman Fred Eshelman is the founder and chairman of Furiex Pharmaceuticals (NASDAQ: FURX). Previously he was the founder, Chairman, and CEO of Pharmaceutical Product Development (NASDAQ: PPDI) prior to its sale to private equity in 2011. PPD provided drug discovery and development services to biopharmaceutical and government organizations. His career has also included positions as senior vice president of development and board member of the former Glaxo Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and currently serves on a number of industry boards. He chairs the board of visitors for the School of Pharmacy at the University of North Carolina, his alma mater, and serves as an adjunct professor. One of the top pharmacy programs in the United States, in May 2008 the school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the pharmacy profession. Eshelman is also a member of the University of North Carolina System Board of Governors. He has received many awards including the Davie and distinguished service awards from UNC, and outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy. Eshelman received a doctor of pharmacy from the University of Cincinnati and a B.S. in pharmacy from the University of North Carolina at Chapel Hill. He is a graduate of the Owner/President Management Program at Harvard Business School.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory